Applied Materials Just Beat Earnings, Raised Guidance, and Got Sold Anyway — Welcome to the AI Trade's Silly Season

Here's a sentence that should break your brain a little: Applied Materials just posted record revenue, crushed EPS estimates, and guided next quarter well above what Wall Street was modeling — and the stock got sold. Not "up 2% instead of 8%." Sold. That's the market we're in right now, and if you don't understand why, you don't understand the AMAT trade.

Let's do the numbers first, because they're genuinely excellent. Q3 FY2026 revenue came in at $9.12 billion, a record, against consensus of roughly $8.99 billion. Non-GAAP EPS of $3.50 was up 41% year-over-year and beat estimates too. That's not a company limping across the finish line — that's acceleration. Revenue went from $7.91 billion in Q2 to $9.12 billion in Q3, and now management is guiding Q4 to a midpoint of $10.25 billion, with a range up to $10.75 billion, versus a Street that was sitting at roughly $9.5 billion. EPS guidance of $3.82–$4.22 also blew past the $3.65 consensus. Management even raised its full-year Semiconductor Systems outlook and said, in so many words, that AMAT will grow faster than the market this year. Jefferies liked that enough to bump estimates afterward.

So why did the stock drop?

Because AMAT walked into this print up roughly 105% year-to-date, having basically doubled off a chart that broke through $739 before consolidating. When a stock has already priced in the AI supercycle, the sequel, and the director's cut, "good, but not great" — which is literally how Morgan Stanley described this quarter — is not good enough. The buy-side wasn't pricing consensus. It was pricing perfection, or something close to it. That's the real lesson of the Q3 report: beating estimates and beating expectations are two very different games, and AMAT played the first one flawlessly and still lost the second.

This is not a red flag on the business. It's a red flag on the crowd. And that distinction matters enormously for what you do next.

The bull case hasn't moved an inch. Semiconductor equipment spending is tracking 30%+ growth for 2026, DRAM and HBM mix is expanding as AI accelerators gobble memory, and big tech capex has blown past $700 billion this year. AMAT's EPIC Center R&D partnerships just grew to 11 engagements with leading chipmakers — that's the moat compounding while the stock chops around. Analyst targets have been revised upward, with the average 12-month price target sitting around $640, a real gap above where shares trade now. None of the bear-case triggers — Q4 guide below $8.5B, flat full-year outlook, margin compression under 50% — actually showed up. They were the things that could have gone wrong. They didn't.

The bear case is narrower but not nothing. China exposure remains the perpetual overhang — export controls are a standing risk, not a resolved one. Valuation is the bigger issue: at roughly 2x where the stock started the year, and a forward P/E north of 31, there's very little room for error priced in. Short interest is low at 1.8%, which cuts both ways — it means there's no crowded short to squeeze, but it also means there's no natural buyer waiting in the wings if sentiment sours further.

Here's my take: this looks like digestion, not a top. A parabolic 105% move doesn't unwind in an orderly fashion — it unwinds via exactly this kind of "great quarter, weak reaction" whiplash, as the fast money that rode the move takes profits into strength and lets the stock breathe. The 200-day moving average around $525 is the line in the sand. Above it, this is a name with a raised full-year outlook and a $10.25 billion quarter on deck. Below it, the "priced for perfection" bears get their moment.

I'm not chasing AMAT at the top of its range on hope. But I'm also not fading a company that just told you, with real numbers, that AI-driven equipment demand is accelerating, not slowing. The next real referendum is the fiscal Q4 report on November 12, when the market finds out whether that $10.25 billion guide was sandbagged or stretched. Until then, this is a stock arguing with its own success — and honestly, that's a much better problem to have than the alternative.